Shaanxi Mei Bang Pharmaceutical Group605033.SHValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 19, 2026, Shaanxi Mei Bang Pharmaceutical Group (605033.SH) trades at a P/E of 40.10x, P/B of 2.15x, P/S of 2.30x, and a dividend yield of 0.80%.
Longitudinal percentile comparison: P/E sits at the 49th percentile over the trailing 10Y window (vs. 16th percentile over 3Y); P/B sits at the 31st percentile over the trailing 10Y window (vs. 44th percentile over 3Y); P/S sits at the 38th percentile over the trailing 10Y window (vs. 44th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 55th percentile within its industry and the 53rd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.80%, ranking at the 38th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 18.0 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Shaanxi Mei Bang Pharmaceutical Group operates in the Basic Chemical Engineering sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHA: 605033 · SSE: 605033 · 605033
Want the full picture on whether Shaanxi Mei Bang Pharmaceutical Group (605033.SH) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 40.10 | ||||||
| P/B (MRQ) | 2.15 | ||||||
| P/S (TTM) | 2.30 | ||||||
| Dividend Yield | 0.80% | ||||||
| Buyback + Div Yield | 0.80% |